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ABSTRACT
CD47 is known to play an important role in CD4+ T cell
homeostasis. We recently reported a reduction in mice
deficient in the Cd47 gene (Cd472/2) CD4+ T cell adhe-
sion and transendothelial migration (TEM) in vivo and in
vitro as a result of impaired expression of high-affinity
forms of LFA-1 and VLA-4 integrins. A prior study
concluded that Cd472/2 mice were resistant to experi-
mental autoimmune encephalomyelitis (EAE) as a result
of complete failure in CD4+ T cell activation after myelin
oligodendrocyte glycoprotein peptide 35–55 aa
(MOG35–55) immunization. As the prior EAE study was
published before our report, authors could not have
accounted for defects in T cell integrin function as a
mechanism to protect Cd472/2 in EAE. Thus, we hypoth-
esized that failure of T cell activation involved defects in
LFA-1 and VLA-4 integrins. We confirmed that Cd472/2
mice were resistant to MOG35–55-induced EAE. Our data,
however, supported a different mechanism that was not
a result of failure of CD4+ T cell activation. Instead, we
found that CD4+ T cells in MOG35–55-immunized Cd47
2/2
mice were activated, but clonal expansion contracted
within 72 h after immunization. We used TCR crosslinking
and mitogen activation in vitro to investigate the un-
derlying mechanism. We found that naı¨ve Cd472/2 CD4+
T cells exhibited a premature block in proliferation and
survival because of impaired activation of LFA-1, despite
effective TCR-induced activation. These results identify
CD47 as an important regulator of LFA-1 and VLA-4
integrin-adhesive functions in T cell proliferation, as well
as recruitment, and clarify the roles played by CD47 in
MOG35–55-induced EAE. J. Leukoc. Biol.
101: 493–505; 2017.
Introduction
CD47 is a ubiquitously expressed glycoprotein that interacts “in
cis” with multiple integrins and “in trans” with SIRPa and SIRPg
and TSP-1 and TSP-2 (reviewed in refs. [1, 2]). Previous studies
have shown that CD47 interactions with SIRPs and TSP-1 play an
important role in leukocyte recruitment in models of inflam-
mation and platelet adhesion and activation, in immune cell
homeostasis and apoptosis, and as a modulator of CD4+ T cell
functions (reviewed in ref. [3]). CD47 also is a marker of “self”
and has been proposed as a cancer therapy target in murine
hematopoietic cancer models [4–9].
Recently, we reported that CD47 is in close physical contact
with b2 integrins and that CD47 is required for expression of
high-affinity forms of LFA-1 and VLA-4 integrins in human T cells
[10]. In addition, murine Cd472/2 CD4+ Th1 cells have reduced
adhesive interactions with TNF-a-inflamed cremaster muscle
microvessels and a 50% reduction of TEM in vitro [11].
Importantly, it is well documented that both LFA-1 and VLA-4
are involved in T cell antigen priming by APCs and homing to
lymphoid tissues and to sites of immune reactions and
inflammation.
Recruitment and reactivation of self-reactive T effector cells in
the CNS are considered central mechanisms in the pathogenesis
of MS. EAE is an established murine model for MS [12]. EAE is
triggered primarily by autoreactive CD4+ Th subsets [13]. Given
the importance of CD47 in immune cell function and in
expression of high-affinity forms of VLA-4 and LFA-1 and that the
phenotype of Cd472/2 animals has not been explored in detail in
neurologic autoimmune disease models, we examined whether
CD47 regulates antigen-dependent T cell responses in a model of
MOG35–55-induced EAE. A previous study by Han and colleagues
[14] reported that Cd472/2 mice were resistant to active
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induction of EAE by MOG35–55 immunization. They also
reported that passive induction of EAE by transfer of in vivo
MOG35–55-activated Cd47
2/2 T cells failed to induce disease in
WT or recombination-activating gene-deficient mice, whereas
transferring WT T cells induced disease in WT and Cd472/2
recipients. The authors attributed protection in EAE to complete
failure of Cd472/2 CD4+ T cell activation. Their conclusion that
in vivo MOG35–55-activated Cd47
2/2 T cells transferred to WT
recipients did not cause disease is flawed and inconsistent with
literature. This is because Cd472/2 T cells transferred into WT
mice cannot bind SIRPa, expressed by splenic macrophages or
DCs to deliver a negative “don’t eat me” signal and thus, are
rapidly phagocytosed and removed from the circulation, as
reported previously [4, 5, 15]. With the use of the same in vivo
EAE model, we confirm that Cd472/2 mice are completely
resistant to MOG35–55-induced EAE, but in contrast to Han and
colleagues’ study [14], we demonstrate that CD4+ T cell
activation does occur in MOG-immunized Cd472/2 animals.
Surprisingly, activated CD4+ T cells failed to sustain proliferation
or clonal expansion. Specifically, MOG35–55 immunization of
Cd472/2 mice induced CD4+ T cell activation and T cell entry
into cell cycle and cell division, but activated T cells exhibited a
striking reduction in clonal expansion within 48 h. We found that
defective integrin activation in Cd472/2 CD4+ T cells after TCR-
XL treatment or mitogen treatments in vitro was responsible for
impaired homotypic aggregation, poor proliferation, and sub-
sequent increased apoptosis. Our results indicate that reduced
LFA-1 integrin-mediated adhesion and a defect in proliferation
of Cd472/2 CD4+ T cells upon MOG35–55 immunization—not
failure in CD4+ T cell activation, as reported previously [14]—are
the major mechanisms of protection in MOG35–55-induced EAE.
MATERIALS AND METHODS
Mice
C57BL/6 WT mice from Charles River Laboratories (Wilmington, MA, USA)
were used to establish a WT breeding colony in the pathogen-free animal
facility at Harvard Medical School, New Research Building (Boston, MA,
USA). Generation of Cd472/2 mice on the C57BL/6J background has been
previously described [16]. Cd472/2 mice were obtained from Dr. Eric Brown,
while he was a faculty member at University of California (San Francisco, CA,
USA) and were used to establish our colony that was used to generate the
results (see Figs. 1 and 2). Subsequent studies (see Figs. 3–7) were carried out
with Cd472/2 mice, purchased from The Jackson Laboratory (Bar Harbor,
ME, USA), which also were completely protected in the EAE model. Animals
from both sources had been backcrossed .10 generations. MOG35–55-specific
TCR Tg mice (2D2 mice) were provided by Dr. Vijay Kuchroo (Brigham and
Women’s Hospital, Boston, MA, USA) [17]. Mice were used at 6–10 wk old for
EAE induction or euthanized at 8–12 wk of age for harvest of cells or as
otherwise noted.
Study approval
Animal research was performed in accordance with the guidelines of the
Committee of Animal Research at the Harvard Medical School and the U.S.
National Institutes of Health animal research guidelines, as set forth in the Guide
for the Care and Use of Laboratory Animals. Blood was drawn and handled according
to protocols for protection for human subjects, approved by the Brigham and
Women’s Hospital Institutional Review Board. Informed consent was obtained
from all volunteers in accordance with the Declaration of Helsinki.
Materials
RPMI 1640, cell tracer CFSE proliferation kit, ammonium-chloride-potassium
lysing buffer, and nonessential amino acids were from Thermo Fisher
Scientific (Waltham, MA, USA). DPBS+ and DPBS2 Ca2+ and Mg2+ were
purchased from Lonza (Walkersville, MD, USA). Con A and PHA-P were
obtained from Sigma-Aldrich (St. Louis, MO, USA). PMA, ionomycin, PI, and
FCS were purchased from Sigma-Aldrich. MOG35–55 (M-E-V-G-W-Y-R-S-P-F-S-R-
O-V-H-L-Y-R-N-G-K), corresponding to the mouse sequence, was synthesized
by Quality Controlled Biochemicals (Hopkinton, MA, USA) and was purified
to .99% by HPLC. The following rat mAb were purified, azide-free IgG and
purchased from BioLegend (San Diego, CA, USA): rat anti-mouse mAb to IL-4
(clone 11B11), CD3e (clone 145-2C11), CD28 (clone E18), CD47 (miap301),
LFA-1 (clone M17/4), and VLA-4 (clones R1-2 and 9C10). Other mAb were
used as purified IgG: rat anti-mouse ICAM-1 (clone YN1.1), anti-human b2
integrin (TS1/22), anti-human VLA-4 (HP2/1), and anti-human MHC class I
(W6/32) mAb, purchased from ATCC (Manassas, VA, USA); B6H12 and
C5D5, function-blocking mAb to human CD47, obtained from ATCC and
from Dr. Parkos [18], respectively; 2D3, a nonblocking anti-CD47 mAb,
obtained from Dr. Eric Brown [19]; and anti-Bcl-xL (clone 2H12) from
Southern Biotech (Birmingham, AL, USA). Mouse rIL-12 and rIL-2 were from
BioLegend. Murine rIL-7, rIL-18, and rIL-23 and murine and human VCAM-1-
Fc and ICAM-1-Fc were from R&D Systems (Minneapolis, MN, USA). Murine
CXCL12 and CCL21 were from PeproTech (Rocky Hill, NJ, USA). Fluorescent
PE-Annexin V apoptosis detection and FITC-BrdU flow kits and the following
fluorescent dye-conjugated primary mAb were purchased from BD
PharMingen (San Jose, CA, USA): anti-mouse PE-IL-2, allophycocyanin-IL-4,
PE-IL-9, allophycocyanin-IL-10, PE- and allophycocyanin-IL-17A, PE-IFN-g,
allophycocyanin-forkhead box P3, PE-CD25, FITC-CD62L, PE-Cy7-CD69, PE-
and allophycocyanin-CD4, FITC- and Pacific Blue-CD8, FITC- and PE-CD11c,
allophycocyanin-CD11b, FITC- and allophycocyanin-CD47, PE-Cy7-B220,
FITC- and PE-CD44, PE-PD-1, PE-CD28, PE-ICOS, PE-CTLA-4, and PE-CD40L.
Cell isolation
Human CD3+ T cells were isolated to .95% purity by negative selection
using RosetteSep negative depletion kits (Stemcell Technologies, Vancou-
ver, BC, Canada) from anti-coagulated whole blood obtained from healthy
volunteers [20]. Murine splenic CD11c+ DCs and CD4+ T cells were purified
by magnetic bead positive separation kits (Miltenyi Biotec, Cambridge, MA,
USA). Naı¨ve CD4+ T cells were polarized to Th1 cells by culture with plate-
bound anti-CD3e mAb (5 mg/ml), and RPMI-1640 medium containing
anti-CD28 mAb (1 mg/ml), anti-IL-4 mAb (1 mg/ml), and cytokines IL-12
(10 ng/ml) and IL-2 (25 U/ml), as previously detailed [21]. Polarization to
Th1 cells was confirmed by measurement of intracellular IFN-g production
by flow cytometry.
T cell adhesion to immobilized Fc chimera adhesion
molecules under defined laminar shear flow conditions
in vitro
T cell arrest on immobilized adhesion molecules in a parallel flow chamber
has been described previously [21]. In brief, 5 3 105/ml T cells in DPBS with
0.1% BSA and 20 mM HEPES were drawn across immobilized ligands ICAM-1-
Fc (10 mg/ml) or VCAM-1-Fc (5 mg/ml) under flow at 37°C. T cell arrest was
monitored by video microscopy [10], and cell adhesion/mm2 was measured
from review of recorded videos.
Induction of EAE and spinal-cord histologic analysis
EAE was induced as described [22]. In brief, 6- to 10-wk-old WT and Cd472/2
mice were immunized subcutaneously with 100 mg MOG35–55 emulsified in
(continued from previous page)
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CFA (H37Ra; Difco Laboratories, Detroit, MI, USA). Animals received 200 ng
by i.p. injection of PT (List Biologic, Campbell, CA, USA) on d 0 and 2 DPI.
Mice were observed daily, and EAE clinical signs were scored as follows: grade
0, no disease; grade 1, limp tail or isolated weakness; grade 2, partial hind-limb
paralysis; grade 3, total hind-limb paralysis; grade 4, total hind-limb and partial
fore-limb paralysis; grade 5, moribund or dead animal. To induce EAE by
adoptive transfer of activated T cells, CD4+ T cells were isolated from spleens
of naı¨ve 2D2 mice and activated in vitro for 48 h in medium containing
MOG35–55 peptide (20 mg/ml), IL-2 (20 ng/ml), and IL-7 (5 ng/ml).
Activation was repeated and was followed by a final activation with plate-bound
anti-CD3e and anti-CD28 mAb (1 mg/ml each mAb) for 24 h in media with
IL-12 (20 ng/ml), IL-18 (25 ng/ml), and IL-23 (10 ng/ml). These activated
2D2 Tg T cells were harvested, and 2 3 106 cells were transferred to naı¨ve
WT or Cd472/2 mice by i.p. injection. Animals also received 69 ng i.p. of PT
on d 0 and d 2 after cell transfer, and clinical signs were scored daily. For
histologic studies, mice were euthanized on DPI 15 and perfused transcardially
with 4% PFA in PBS. Spinal cords were removed and fixed in 1% of PFA for
24 h, embedded in paraffin, sectioned, and stained with H&E.
T cell proliferation in vivo by BrdU incorporation
Mice were immunized with MOG35–55 and 48 h later, were injected with BrdU
(2.5 mg/mouse i.p.). CD4+ T cells were isolated 24 h later from dLNs, and
BrdU incorporation in CD4+ T cells was measured following the manufac-
turer’s instructions (BD PharMingen). Cell fluorescence was determined by
flow cytometry (FACSCalibur flow cytometer; BD Biosciences, San Jose, CA,
USA) and data analyzed by FlowJo software (Tree Star, Ashland, OR, USA).
T cell proliferation assays
Spleens from immunized mice were harvested, and aliquots of total
splenocytes (1 3 105) were cultured with MOG35–55 for 48 h. Cultures were
pulsed with 1 mCi [3H]-thymidine in the last 16 h of incubation and harvested
by automated sample harvester (Perkin-Elmer, Waltham, MA, USA) [22]. For
coculture-recall assays of DC priming of the CD4+ T cell, purified CD4+ T cells
and CD11c+ DCs from immunized mice were cultured with 5 mg/ml
MOG35–55 for 48 h. Proliferation was monitored by [
3H]-thymidine in-
corporation. For in vitro proliferation assays, purified CD4+ T cells from
spleens of naı¨ve WT and Cd472/2 mice were activated by polyclonal activation
TCR-XL using plate-bound anti-CD3e mAb (1 mg/ml) and soluble anti-CD28
mAb (1 mg/ml) or by coculture with mitogens Con A (5 mg/ml) or PHA-P
(20 mg/ml) or ionomycin (5 mM) plus PMA (50 ng/ml). Proliferation was
monitored by [3H]-thymidine incorporation. Blocking mAb to LFA-1, CD47,
ICAM-1, and a combination of 2 different function-blocking anti-VLA-4 mAb
were used as purified and azide-free IgG at 20 mg/ml. T cell proliferation was
also determined by a flow cytometric assay of CFSE dilution. Purified CD4+
T cells were added to a solution of 5 mM CFSE in PBS at 37°C for 10 min,
followed by extensive washing with warm PBS. Cells were cultured as described
in text and harvested at different time points after TCR-XL. CFSE
fluorescence of gated CD4+ cells was analyzed with FlowJo software to obtain
proliferation indices (see Table 2 and Fig. 6).
Intracellular cytokine staining and cytokine
production assays
For intracellular cytokine staining, cells were activated with 100 ng/ml PMA
and 5 mg/ml ionomycin for 4 h in the presence of GolgiStop (BD
PharMingen) and stained by anti-cytokine mAb and appropriate isotype-
matched control antibodies [21]. Cell fluorescence was measured in the CD4+
population by flow cytometry. For analysis of IL-4-, IL-6-, IL-17A-, and IFN-
g-producing cells, splenocytes (2 3 105) from immunized mice were activated
with MOG35–55 for 24 h in antibody-coated ELISPOT plates, and spots were
counted by an ELISPOT image analyzer (Cellular Technology, Cleveland,
OH), as reported previously [22]. Leukocyte subtypes and expression of
surface activation markers and costimulatory proteins were measured by
appropriate mAb and flow cytometry [21, 22]. Intracellular staining of anti-
apoptotic Bcl-xL protein was performed exactly as reported [23]. In brief,
T cells were harvested, washed in DPBS, fixed in 2% PFA-PBS for 20 min at
room temperature, washed twice with PBS, and permeabilized with 0.5%
saponin-PBS containing 20% FBS (perm buffer). Cells were incubated with
mouse anti-Bcl-xL (1 mg/ml) or no primary mAb in 50 ml perm buffer for
30 min at room temperature, washed twice with perm buffer, and incubated
at room temperature for 20 min with goat anti-mouse Alexa 647-labeled secondary
mAb in perm buffer. Cells were then washed and analyzed by flow cytometry.
Naı¨ve T cell stimulation by TCR-XL in suspension
Naı¨ve CD4+ T cells (2 3 106 cells/ml) in RPMI 1640 + 0.2% FCS were treated
with anti-CD3e (2.5 mg/ml) and anti-CD28 (2.5 mg/ml) mAb for 15 min on
ice. After washing to remove the first mAb, secondary antibodies (goat anti-
Armenian hamster and goat anti-mouse; Jackson ImmunoResearch Labora-
tories, West Grove, PA, USA) were added (2.5 mg/ml) using the same medium
and incubated for 15 min on ice. T cells were washed once and resuspended
to 2 3 106 cells/ml in RPMI 1640 and kept on ice until stimulation was
initiated at 37°C. Incubations were halted by addition of formaldehyde
(diluted to 4% final concentration) and incubation at 37°C for 15 min. After
chilling for 1 min on ice, T cells were centrifuged, resuspended in ice-cold
90% methanol, and incubated on ice for 30 min. Then, cells were stained with
primary-labeled phospho-specific mAb for 1 h at room temperature, washed,
and resuspended in 1% formaldehyde in PBS for flow cytometry.
T cell-cycle analysis
Naı¨ve T cells were activated by TCR-XL with plate-bound mAb and incubated
for different time points, harvested, fixed by drop-wise addition of 100% ice-
cold ethanol, while vortexing to a final concentration of 75% ethanol, and
incubated on ice for 1 h. Cells were washed in PBS and incubated in PI
solution (50 mg/ml, 100 mg/ml RNase A, and 3.8 mM sodium citrate) for 3 h
on ice. Cell-cycle profiles were assessed by flow cytometry and analyzed by
FlowJo software.
Analysis of CD4+ T cell apoptosis
Naı¨ve, splenic WT and Cd472/2 CD4+ T cells were activated by TCR-XL with
plate-bound anti-CD3e (1 mg/ml unless stated otherwise) and addition of
1 mg/ml anti-CD28 mAb to the media, cultured for various times, and harvested
to assess cell apoptosis. Annexin V staining and detection of DNA
fragmentation using an APO-BrdU TUNEL assay kit (Thermo Fisher
Scientific) were performed by following the manufacturer’s instructions and
analyzed by standard flow cytometry. T cell apoptosis was also assessed by
caspase-3 activity in cell lysates by quantification of light emission at 400 nm
chromophore p-nitroaniline after cleavage by caspase-3 from the labeled
DEVD-p-NA (Kit #ab39401; Abcam, Cambridge, MA, USA).
Statistics
Statistical analyses used Prism 5 software (GraphPad Software, La Jolla, CA,
USA). Data are expressed as means 6 SEM. Data were analyzed by unpaired 2-
tailed Student’s t test between 2 groups and 1-way ANOVA for .2 groups, with
P , 0.05 considered significant.
RESULTS
CD47 regulates TCR-XL and chemokine-induced
LFA-1- and VLA-4-mediated arrest on ICAM-1 and
VCAM-1 in vitro
We previously reported that CD47 is necessary for expression of
high-affinity forms of LFA-1 and VLA-4 integrins in CD4+ Th1 cells
that bind to their endothelial cell-expressed ligands ICAM-1 and
VCAM-1, respectively, after CXCL12 stimulation [10]. To extend
our observations, we investigated whether CD47 is necessary for
TCR-XL-induced, na¨ıve CD4+ T cell arrest on ICAM-1 and VCAM-1
in an in vitro flow-chamber assay. We found that TCR-XL or
Azcutia et al. CD47 regulates LFA-1 in T cell pathogenesis of EAE
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coimmobilized CCL21 chemokine increased adhesion of WT but
not Cd472/2 naı¨ve CD4+ T cells to immobilized ICAM-1 and
VCAM-1 (Fig. 1A). Fewer Cd472/2 T cells bound to VCAM-1
without a stimulus compared with WT T cells. These results show
that CD47 is necessary for TCR-XL and chemokine-induced LFA-1
and VLA-4 activation and adhesion to ICAM-1 and VCAM-1 under
fluid shear flow conditions.
Anti-CD47 mAb miap301 reduces LFA-1 and VLA-4
integrin adhesion to ICAM-1 and VCAM-1
Although the amino acid(s) in CD47 that regulate integrin
activation have not been identified, we tested whether mAb
miap301, which blocks CD47 binding to its in trans ligand SIRPa
[24], interferes with naı¨ve CD4+ T cell adhesion. Pretreatment of
WT CD4+ naı¨ve T cells with miap301 mAb reduced TCR-XL-
induced adhesion to ICAM-1 and VCAM-1 (Fig. 1B) and also
reduced in vitro-generated WT Th1 effector cell adhesion to
ICAM-1 coimmobilized with CXCL12 or to VCAM-1 (Fig. 1C).
Blocking mAb to LFA-1 and VLA-4, but not IgG, blocked T cell
adhesion and demonstrated the specificity of this assay. Likewise,
purified human CD3+ T cells pretreated with different anti-CD47
mAb that block in trans CD47-SIRPa adhesion (B6H12 and
C5D5) also reduced adhesion (Fig. 1D). In contrast, a
nonfunction-blocking anti-CD47 mAb (2D3) had no effect.
These data demonstrate that CD47 is necessary for LFA-1 and
VLA-4 integrin-dependent adhesion of T cells to their endothe-
lial cell-expressed ligands, ICAM-1 and VCAM-1, respectively.
Cd472/2 mice are resistant to MOG35–55-induced EAE
but are susceptible to passive transfer of EAE
Based on our premise, Cd472/2 mice are not susceptible to EAE,
as loss of CD47 impairs LFA-1 and VLA-4 activation and T cell
recruitment (Fig. 1 and refs. [10, 11]), and as an anti-VLA-4
integrin mAb (natalizumab) is used to treat patients with
relapsing and remitting MS, we examined the susceptibility of
Cd472/2mice to MOG35–55-induced EAE. WT male (Fig. 2A) and
female mice (Fig. 2B) immunized with MOG35–55 in CFA
developed typical EAE disease scores. In striking contrast, Cd472/2
mice were completely resistant. Histologic analysis of spinal-
cord sections from DPI 15 (Fig. 2C) revealed abundant mono-
nuclear infiltrates in WT mice but not in Cd472/2 animals. These
findings corroborate the report by Han and colleagues [14]
using this EAE model.
Based on our prior reports that both endothelial cell and T cell
CD47 play important roles in T cell recruitment in in vivo and in
vitro models [10, 11, 25, 26], we hypothesized that multiple
Figure 1. CD47 regulates TCR-XL-induced LFA-1- and VLA-4-mediated arrest on ICAM-1 and VCAM-1 under shear flow conditions in vitro. (A)
Naı¨ve WT and Cd472/2 CD4+ T cells were stimulated by TCR-XL in suspension, and their adhesion to immobilized ICAM-1 or to VCAM-1 was
analyzed under flow conditions at an estimated shear rate of 0.5 (for ICAM-1) and 0.75 (for VCAM-1) dyne/cm2, as previously reported [21]. Data
are means 6 SEM of 3 separate experiments, each done in duplicate coverslips. *P , 0.05; ***P , 0.001 by paired Student’s t test. Adhesion of
T cells to ICAM-1+ CCL21 (250 ng/ml) was the positive control (n = 2 duplicate coverslips). (B) WT naı¨ve CD4+ T cell adhesion to ICAM-1
and VCAM-1 induced by TCR-XL was reduced by anti-CD47 mAb miap301 mAb (20 mg/ml, 30 min, 37°C). Likewise, blocking LFA-1 and
VLA-4 mAb (20 mg/ml) inhibited cell adhesion. Data are means 6 SEM, n = 3 separate experiments performed in duplicate. *P , 0.05; **P , 0.01;
***P , 0.001 compared with WT T cells (black solid bars). (C) Adhesion of in vitro-differentiated WT CD4+ Th1 cells to ICAM-1 + CXCL12 (250
ng/ml) and to VCAM-1 was reduced by blocking CD47 with miap301 mAb and by anti-LFA-1 and VLA-4 mAb. Data are means 6 SEM, n = 3 separate
experiments performed in duplicate. *P , 0.05; ***P , 0.001 vs. IgG control (all mAb used at 20 mg/ml). (D) Human peripheral blood CD3+
T cells (.95% purity) were pretreated with mAb to CD47 (B6H12 or C5D5), which blocks CD47 binding to SIRPa [42, 43] or VLA-4 (HP2/1), class
I (W6/32), nonblocking anti-CD47 (2D3), or anti-LFA-1 mAb (TS1/22; all mAb are purified IgG, 20 mg/ml) for 30 min. T cell adhesion to human
ICAM-1-Fc coimmobilized with CXCL12 or immobilized VCAM-1-Fc or E-selectin-Fc chimeras was measured under shear stress conditions, as we
have published [21]. Data are means 6 SEM, performed in duplicate, n = 3–5 separate experiments. *P , 0.05 compared with no addition.
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defects converge to confer resistance in Cd472/2 mice to EAE.
To address whether CD47 expressed in the host is required for
susceptibility to EAE, we adoptively transferred in vitro-polarized
Thy1.1+ MOG35–55-specific CD4
+ T cells from 2D2 Tg mice into
Thy1.2+ WT and Cd472/2 recipient female animals (passive EAE
induction model). The TCR gene expressed in CD4+ T cells in
2D2 Tg mice recognizes MOG35–55 [17]. WT and Cd47
2/2 mice
experienced comparable clinical signs of EAE (Fig. 2D) by DPI
13, indicating the defect(s) reside in the immune cell compart-
ment. We note that transfer of Cd472/2 T cells into WT recipient
animals leads to their rapid clearance from WT animals, as
reported previously [15]; hence, this arm of the study was not
performed. The mechanism involves phagocytosis of intravenous-
transferred Cd472/2 bone marrow or blood cells by splenic DCs
and macrophages [4, 5].
CD4+ T cells do not proliferate in response to
MOG35–55 in Cd47
2/2 mice
We first determined the number of total live cells in axillary and
cervical dLNs from WT and Cd472/2 animals before and 8 d after
MOG35–55 immunization. Although unimmunized, naı¨ve Cd47
2/2
mice (Fig. 3A; open bars) showed a significant reduction (60 6
5%) in cell number in LNs compared with age-matched WT
mice, the frequency of leukocyte types in WT and Cd472/2
remained similar (Table 1). Prior studies also have reported
reduced cell counts in the spleen and peripheral blood of Cd472/2
mice; however, this was because of a specific loss of CD4+
T cells [11, 16, 27].
On DPI 8, despite an increase in total cell number in
immunized Cd472/2 mice, the cell number in dLNs remained
significantly less than that in immunized WT mice (Fig. 3A, solid
bars), and the populations were not skewed by loss of any 1
specific cell type (Table 1). Thus, the calculated absolute number
of CD4+ T cells in Cd472/2 mice was well below that of WT mice
(WT, 5.73 3 106 vs. Cd472/2, 3.21 3 106). Given this significant
reduction in total CD4+ T cells, we probed the animals for
antigen-specific, responsive CD4+ T cells in splenocytes at
different DPI in an in vitro recall response to MOG35–55.
Interestingly, proliferation of Cd472/2 cells at each time point
Figure 2. Cd472/2 mice are not susceptible to EAE. (A) Mice were
immunized with MOG35–55, and the clinical score of male (n = 4 mice/
group) and female (B; n = 10 mice/group) animals is reported (4 of 4
WT males and 10 of 10 WT female mice developed EAE; solid circles).
No Cd472/2 mice developed EAE (open circles). Data are means 6 SEM
of 3 separate experiments. (C) Histopathology of the spinal cord of
WT and Cd472/2 mice, 15 d after MOG35–55 immunization. Original
scale bars, 1 mm (403, left) and 250 mm (2003, right). (D) Both
Cd472/2 and WT mice are susceptible to passive transfer-induced EAE
after i.p. injection with 2 3 106 of MOG35–55 TCR-specific T cells. Data
are means 6 SEM from 4 mice of each group.
Figure 3. Reduced proliferation of Cd472/2 CD4+
T cells in vivo and in vitro upon antigen
presentation. (A) Cervical and axillary LNs were
harvested from naı¨ve mice and mice, DPI 8. Total
leukocyte number was determined by hemocytom-
eter counting. Data are means 6 SEM from 5–10
mice of each group. (B) Total splenocytes were
harvested from mice on DPI 4, 6, and 8 and
assayed for recall proliferation to MOG35–55
(5 mg/ml). Data are means 6 SEM of triplicate
determinations from 2 separate experiments. (C
and D) ELISPOT data represent the number of
cells producing IFN-g or IL-17A, respectively, 48 h
after rechallenge of 2 3 105 splenocytes with
MOG35–55 (5 mg/ml). Data are means 6 SEM of
triplicate determinations from 3 separate experi-
ments. (E) dLNs were collected from naı¨ve and
immunized WT and Cd472/2 mice at DPI 3. Cells
were stained with anti-CD4+ mAb and for BrdU
incorporation, and fluorescence in CD4+ T cells was
quantified by flow cytometry. Data are means 6 SEM
from 7 mice of each genotype performed
in 3 independent experiments. (F) CD4+ T cell proliferation was determined in a rechallenge assay using CD11c+ DCs and CD4+ T cells purified
from spleens of WT and Cd472/2 mice, 8 DPI, with MOG35–55 (5 mg/ml). KO, Knockout. Data are means 6 SEM, triplicate determinations, and are
representative of 3 separate experiments. *P , 0.05; **P , 0.01; ***P , 0.001 vs. WT cells (A–F); #P , 0.05 vs. Cd472/2 cells at d 0 (B).
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was dramatically impaired compared with WT cells (Fig. 3B).
Cd472/2 mice also produced significantly fewer IFN-g- and IL-
17A-producing cells compared with WT mice (Fig. 3C and D), as
well as IL-4- and IL-6-producing cells (data not shown), as
determined by ELISPOT assay. This general reduction in
cytokine profile suggested a defect in proliferation rather than a
skewed T cell effector differentiation. To investigate this
proliferation defect in vivo, we monitored proliferation specifi-
cally in CD4+ T cells by BrdU incorporation and flow cytometric
analysis. CD4+ T cells from dLNs of immunized WT mice
proliferated by DPI 3, whereas no significant increase over
baseline (1.6 6 0.25%) was detected in immunized Cd472/2
mice (Fig. 3E). To distinguish whether lack of priming was a
result of a defect in the Cd472/2 T cell or DC, we performed a
“crisscross” MOG35–55-driven in vitro proliferation assay.
Cd472/2 CD4+ T cells showed a dramatic defect in proliferation
when cultured withWT or Cd472/2 CD11c+ DCs (Fig. 3F). WT T cells
showed less proliferation when cultured with Cd472/2 vs. WT DCs.
Overall, these data demonstrate that Cd472/2 CD4+ T cells
exhibit a significantly reduced proliferative response to
MOG35–55 immunization compared with WT, and the defect
resides primarily in the CD4+ T cell.
CD4+ T cells in Cd472/2 mice are activated after
MOG35–55 immunization
We next investigated whether the observed reduction in CD4+
T cell proliferation in Cd472/2 mice was caused by failure of
immune cells to activate, as reported by Han and colleagues [14],
or to an inability of activated T cells to proliferate and expand in
response to antigen. Intracellular IL-2 production was the same
in naı¨ve Cd472/2 and WT CD4+ T cells (;7% positive in WT and
Cd472/2 cells) and was elevated to similar levels in WT and
Cd472/2 T cells isolated from spleen and from dLN on DPI 8.
Figure 4A shows the gating scheme, and Fig. 4B shows the results.
WT and Cd472/2 CD4+ T cells produced comparable levels of
intracellular IL-17A and IL-4 cytokines, whereas Cd472/2 pro-
duced greater amounts of IL-9, IL-10, and IFN-g. (Fig. 4C).
Surprisingly, the percent of isolated, naı¨ve CD4+ T cells that
expressed surface activation markers CD44hi, CD69, and CD25
was significantly greater in Cd472/2 compared with WT animals
(Fig. 4D). This finding is consistent with CD47 acting as a
negative regulator of Th1 effector-type responses, as reported
previously [15]. On DPI 8, the percentage of Cd472/2 T cells
expressing CD44hi, CD69, and CD25 increased significantly
compared with naı¨ve mice and was the same as or greater than
WT cells. Taken together, these data demonstrate that CD4+
T cells in MOG35–55-immunized Cd47
2/2mice are activated to an
equal or greater level than WT T cells, produce intracellular
cytokines, yet proliferate poorly and have limited clonal
expansion compared with WT CD4+ T effector cells.
Cd472/2 T cells are activated by TCR-XL with
CD28 costimulation
We next investigated whether Cd472/2 CD4+ T cells have a defect
in antigen-independent activation by TCR-XL, a potent stimulus
that bypasses APC priming and uniformly activates and induces
robust proliferation of CD4+ T cells in vitro. As expected, based
on the in vivo findings, TCR proximal signaling, measured by
increased phosphorylation of Lck, ZAP70, ERK1/2, and AKT
kinases, was essentially identical in WT and Cd472/2 CD4+ T cells
(Fig. 5A). Moreover, distal activation markers, including
increases in surface-expressed CD44hi, CD25, CD69, and PD-1;
down-regulation of CD62L surface expression; and elevated
intracellular IL-2 production were nearly identical in WT and
Cd472/2 T cells (Fig. 5B and C). However, despite the fact that
CD4+ Cd472/2 and WT T cells were activated to a similar level by
TCR-XL and express similar levels of CD28, ICOS, CTLA-4, and
CD40L costimulatory molecules (data not shown), Cd472/2
T cell proliferation was 32–48% less than WT T cells (Fig. 5D).
These findings demonstrate that Cd472/2 CD4+ T cells do not
exhibit a global defect in TCR proximal or distal signal
transduction required for IL-2 autocrine production and in-
creased expression of surface markers of activation or intracel-
lular cytokine production.
Impaired proliferation in Cd472/2 T cells upon
TCR-XL activation in vitro
To identify the underlying defects in Cd472/2 T cell proliferation
farther downstream of TCR-XL, we investigated the cell-cycle and
cell proliferation. Cd472/2 T cells displayed no significant
differences from WT in the cell-cycle progression, up to 48 h, as
illustrated in Fig. 6A; however, Cd472/2 T cells exhibited a
striking reduction in proliferation, as demonstrated by the
differences in the kinetics of TCR-XL-induced CFSE dye dilution
(Fig. 6B). The calculated indices using FlowJo software are
summarized in Table 2. These data demonstrate that the number
of live Cd472/2 T cells dropped by 50% beyond d 2 compared
with WT, even though the Cd472/2 and WT T cells exhibited
similar division and proliferation indexes. Consistent with this
dramatic reduction in cell number, which is consistent with
results in Figs. 3A, D, and E and 6A and B, a significant increase
in apoptosis of Cd472/2 T cells occurred after TCR-XL, as
detected by Annexin V binding (Fig. 6C). This increase in
apoptosis of Cd472/2 compared with WT CD4+ T cells was
corroborated by increased TUNEL staining of fragmented DNA
and by elevated caspase-3 activity (Fig. 6D and E). The anti-
apoptotic proteins of the Bcl-2 family are actively regulated in
T cells (reviewed in ref. [28]). As previous studies showed that
the Bcl-xL gene was an important survival factor induced in CD4+
TABLE 1. Frequency of leukocyte types in LNs from naı¨ve or
MOG-immunized mice
Naı¨ve MOG-immunized
% WT Cd472/2 WT Cd472/2
CD4+ 32.9 6 2.2 31.0 6 2.9 31.8 6 3.2 27.4 6 3.9
CD8+ 26.2 6 1.9 26.2 6 2.6 26.3 6 1.5 24.2 6 2.6
CD11c+ 3.8 6 0.6 5.3 6 1.9 1.5 6 1.2 1.6 6 1.1
B220+ 32.4 6 2.3 36.3 6 3.6 41.0 6 1.8 34.0 6 4.7
LNs were harvested from naive and MOG-immunized WT and Cd472/2
mice, DPI 8, and total leukocyte number was determined by hemocytometer
counting. Data are means 6 SEM. The data are pooled from 5–10 mice in
each cohort, from 3 independent studies. Analysis was performed with mAb
that recognize CD4 and CD8 T cells, CD11c myeloid, and B220 B cells. Other
cell types not identified represented ,1–5% of the total LN populations.
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T cells by TCR-dependent activation, we examined whether its
expression was impaired in Cd472/2 T cells [23, 29–31]. As
shown in Fig. 6F, this was not the case, as Bcl-xL protein was
elevated, to a similar level, in both cell types by TCR-XL
activation. This result suggests other family members, including
anti- and proapoptotic, are involved, and their identity requires
additional detailed studies.
CD47 and LFA-1 are essential for CD4+ T cell
proliferation in vitro
As lack of CD47 impaired the expression of high-affinity LFA-1
and VLA-4 conformations in the human Jurkat CD4+ T cell line
[10], we examined TCR-XL-induced homotypic aggregation of
naı¨ve WT and Cd472/2 CD4+ T cells after 48 h of in vitro culture.
From the literature, LFA-1 and VLA-4 integrin-dependent
homotypic T cell aggregation is an established hallmark of
efficient TCR- and mitogen-mediated activation and proliferation
in vivo and in vitro [32–36]. Cd472/2 T cells exhibited smaller
homotypic aggregates (Fig. 7A) and a 48% reduction in
proliferation of Cd472/2 CD4+ T cells compared with WT T cells
after TCR-XL (Fig. 7B; “no Ab”). Inclusion of function-blocking
mAb to either LFA-1 or ICAM-1 significantly reduced pro-
liferation of WT T cells but not to the level of Cd472/2 cells. Anti-
LFA-1 or ICAM-1 mAb did not further block proliferation by
Figure 4. Cd472/2 CD4+ T cells are activated upon antigen stimulation in vivo. (A) The gating scheme to identify CD4+ T cells and expression of
surface activation markers, for example, CD44hi, is shown. SSC, Side-scatter; FSC, forward-scatter; 7AAD, 7-aminoactinomycin D. (B) dLNs and
spleens were harvested from mice, DPI 8, and the production of intracellular IL-2 by CD4+ T cells was determined by flow cytometry after 4 h of
PMA-ionomycin stimulation. (C) Intracellular production of cytokines in CD4+ T cells from dLN (left) and spleen (right) from MOG35–55-
immunized mice, DPI 8, was determined by flow cytometry after PMA-ionomycin stimulation. *P , 0.05; **P , 0.01 for Cd472/2 values compared
with WT. (D) Surface expression of CD44hi, CD25, and CD69 on CD4+ T cells was determined by flow cytometry. Representative contour plots of
CD4+ T cells prepared from 5–10 mice of each genotype. Data in parentheses are means 6 SEM from 5–10 mice of each genotype. *P , 0.05;
**P , 0.01 for Cd472/2 values compared with WT counterpart surface antigen in naı¨ve and MOG35–55-immunized mice.
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Cd472/2 T cells. WT and Cd472/2 T cell proliferation was not
reduced by 2 different function-blocking mAb to VLA-4 that we
have previously shown to block VLA-4–VCAM-1 interactions [10]
(Fig. 7B). A more striking observation was the near-complete lack
of proliferation by Cd472/2 T cells incubated with PHA-P or Con
A lectins, which initiate proliferation by capping surface proteins,
including the TCR, CD2, signaling lymphocyte activating
molecule family (SLAMs), and other costimulatory molecules
(Fig. 7C and D). We next validated the role of LFA-1 and ICAM-1
in proliferation of WT T cells induced by PHA-P or Con A.
Proliferation was totally abolished by anti-LFA-1 to the level of
Cd472/2 T cells and significantly reduced by ICAM-1 mAb. In
contrast, a combination of 2 function-blocking VLA-4 mAb again
had no inhibitory effect (Fig. 7C and D). Given these results, we
next asked if failure of Cd472/2 T cells to proliferate was an
intrinsic T cell defect by culturing these cells with PMA plus
ionomycin, a stimulus that bypasses surface receptors and
activates key intracellular pathways of proliferation. PMA plus
ionomycin induced robust clustering and proliferation in both
WT and Cd472/2 CD4+ T cells. This indicates that Cd472/2
T cells do not have intrinsic defects in proliferation or cytokine
production pathways (Figs. 4 and 5). As our prior studies revealed
that CD47 is in close physical contact with and regulates b2
integrin activation [10], these results further underscore the
critical requirement for CD47 in TCR-XL and mitogen-stimulated
T cell clustering and clonal expansion in this model and in vitro
proliferation assays.
In the final set of experiments, we tested whether targeting
CD47 altered T cell proliferation. A rat anti-mouse CD47 mAb
(clone miap301) was shown to inhibit completely CD47-
dependent thymocyte and erythrocyte binding to immobilized
SIRPa, its “trans” ligand [24]. Whereas this mAb reduced T cell
Figure 5. Cd472/2 CD4+ T cell activation is intact in vitro. CD4+ T cells were isolated from spleens of naı¨ve WT or Cd472/2 mice, and their
response to TCR-XL stimulation was assessed. (A) Detection of phosphorylated (p) kinases in WT (open bars) and Cd472/2 T cells (solid bars)
upon TCR-XL in suspension by intracellular staining with mAb. Data represent the fold-increase over time 0 s. Means 6 SEM, n = 3 independent
studies. (B) Surface expression of CD44hi, CD25, CD69, PD-1, and CD62L on naı¨ve CD4+ T cells was determined by flow cytometry at 0, 24, or 48 h
after TCR-XL (plate-bound anti-CD3e and soluble anti-CD28 mAb). Data are means 6 SEM from n = 5 independent experiments. (C)_Intracellular
IL-2 production in CD4+ T cells after 0, 24, or 48 h after TCR-XL was determined by standard flow cytometry after PMA-ionomycin stimulation. Data
are means 6 SEM, n = 3 independent experiments. (D) CD4+ T cell proliferation was measured by [3H]-thymidine incorporation, 48 h after TCR-XL
stimulation. Data are means 6 SEM of duplicate samples from 3 independent experiments. **P , 0.01 for Cd472/2 values compared with WT cells.
TABLE 2. CD4+ T cell proliferation upon TCR-XL
Live CD4+ gated cell % Proliferating Division index Proliferation index
Day WT KO WT KO WT KO WT KO
1 15.8 6 0 13.4 6 0 6.8 6 0 5.3 6 0 0.1 6 0 0.1 6 0 1.1 6 0 1.1 6 0
2 32.2 6 8.8 25.6 6 6.6 72.4 6 11.1 72.7 6 8.5 1.5 6 0.3 1.3 6 0.2 2.0 6 0.2 1.8 6 0.2
3 36.4 6 7.2 19.2 6 4.4a 76.4 6 7.5 79.9 6 7.7 1.8 6 0.1 1.6 6 0.1 2.3 6 0.1 2.0 6 0.0
4 24.0 6 6.3 11.2 6 3.5a 77.0 6 8.6 73.7 6 10.7 2.0 6 0.3 1.7 6 0.2 2.6 6 0.1 2.3 6 0.1
5 14.9 6 0.3 9.0 6 3.4 77.2 6 4.0 81.5 6 8.2 2.1 6 0.3 1.9 6 0.2 2.6 6 0.1 2.3 6 0.1
KO, Knockout. Values represent means 6 SEM for n = 3 separate experiments. aP , 0.05 vs. WT.
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arrest on ICAM-1 and VCAM-1 (Fig. 1), surprisingly, miap301
mAb did not reduce TCR-XL-, PHA-P-, and Con A-stimulated
proliferation (Fig. 7F, filled bars, and G). Thus, this mAb does
not reproduce the effect on T cell proliferation observed in
Cd472/2 CD4+ T cells. Whereas a prior study in human T cells
reported that some but not all mAb to CD47 were capable of
costimulation with anti-CD3e mAb [37], we did not detect any
effect on proliferation (Fig. 7F, open bars).
DISCUSSION
Our observation that mice lacking CD47 are protected in EAE is
consistent with defects in T cell LFA-1 and VLA-4 integrin-
adhesive functions and emphasizes the importance of CD47 in
adaptive immune cell responses in a self-antigen-driven murine
disease model. The data herein demonstrate that CD4+ T cells
become activated in MOG35–55-immunized Cd47
2/2 animals and
produce normal or enhanced levels of intracellular cytokines.
Remarkably, CD4+ T cell proliferation was severely blunted
starting 48 h after MOG35–55 immunization in Cd47
2/2 mice and
resulted in increased apoptosis and a very low frequency of
antigen-primed T cells that was insufficient to initiate clinical
symptoms or evidence of histologic CNS disease (Figs. 2 and 3).
We do not exclude, however, the contribution of impaired T cell
homing and recruitment of T effectors cells, including regulatory
T cells, Th1 or Th17, as well as myeloid cells to the CNS during
initiation and/or effector phases of EAE. Future studies are
needed to address this possibility.
Based on our recent report that CD47 associates b2 integrin in
T cells and that CD47 is necessary to induce high-affinity
conformations of LFA-1 and VLA-4 integrins required for
adhesion and TEM [10], we initially postulated that defects in
VLA-4 and LFA-1 function were responsible for the blockade in
proliferation and increased apoptosis. Indeed, integrins are well
documented to participate in homotypic aggregation and
proliferation of T cells and in resistance to apoptotic stimuli,
especially signals that activate the intrinsic (mitochondrial) death
pathway (reviewed in ref. [38]). Our investigation shows both
MOG35–55 immunization and TCR-XL stimulation in vitro failed
to induce proliferation and clonal expansion comparable with
their WT counterpart. Whereas our early results revealed that
MOG immunization of Cd472/2 mice led to an increase in cell
numbers in the dLN (Fig. 3A), further results from in vivo and in
vitro experiments showed that Cd472/2 CD4+ T cells were not
able to cause disease, mostly likely as a result of failure to
Figure 6. Cd472/2 CD4+ T cell proliferation after TCR-XL using plate-bound anti-CD3« and soluble anti-CD28 mAb is impaired in vitro. (A) Cell
cycle was analyzed in CD4+ T cells at 0 [overnight (o/n)], 24, and 48 h after TCR-XL by the analysis of DNA content using flow cytometry and
FlowJo cell-cycle software. Data are representative of 3 independent experiments. (B) CD4+ T cell proliferation over a 5 d period was determined by
CFSE dye dilution after TCR-XL activation using FlowJo proliferation software. The histogram is representative of 3 independent experiments.
FlowJo-calculated indices are presented in Table 2. CD4+ T cell apoptosis was detected by Annexin V staining and flow cytometry. *P , 0.05; **P , 0.01;
***P , 0.001 compared with WT at each time point by paired Student’s t test. (D) DNA nicking in T cells was detected by the TUNEL assay at
different times after TCR-XL and analyzed by flow cytometry. Data are representative histograms of 2 separate experiments performed in duplicate.
(E) Caspase-3 activity in CD4+ T cells was quantified, 48 h after TCR-XL, with anti-CD3e mAb plus 1 mg/ml anti-CD28 mAb. *P , 0.05; **P , 0.01
compared with WT at each time point by paired Student’s t test. (F) Bcl-xL expression in CD4+ T cells is shown after TCR-XL. MFI, Mean
fluorescence intensity.
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proliferate (Fig. 3B–E) or failure to migrate from dLNs to the
CNS or both. In fact, activation of Cd472/2 CD4+ T cells resulted
in elevated apoptosis, which was not related to impaired
expression of the anti-apoptotic protein Bcl-xL (Fig. 6). There is
significant literature for CD47-mediated cell death in a variety
leukocytes and other cell types, as reviewed by Oldenborg [3],
and therefore, additional experiments are necessary to identify
the molecular mechanisms underlying apoptosis of activated
Cd472/2 T cells that we report here. Lastly, our data demonstrate
that CD4+ T cell proliferation relies, in part, on LFA-1 activation
and binding to ICAM-1, especially in response to mitogens. We
infer that MOG35–55-activated Cd47
2/2 T effector cells that do
proliferate and survive in immunized Cd472/2 mice are likely to
have defects in homing to the CNS, and additional studies are
required to assess this possibility. These findings highlight the
important and multiple roles of Cd47 in T cell activation and the
Figure 7. CD47 is necessary for integrin-mediated splenic CD4+ T cell clustering and proliferation in vitro. (A) Representative images of naı¨ve WT
splenic CD4+ T cell (upper) and Cd472/2 (lower) homotypic cluster formation (white arrows), 48 h after activation induced by TCR-XL (plate-
bound anti-CD3e with soluble anti-CD28 mAb), PHA-P, Con A, or PMA + ionomycin (Iono.). Proliferation of naı¨ve CD4+ WT and Cd472/2 T cells
induced by TCR-XL (B), PHA-P (C), Con A (D), or PMA + ionomycin (E). Note that only WT T cell proliferation was measured in the presence of
blocking mAb to LFA-1 and VLA-4 and their combination and ICAM-1. Data are means 6 SEM of triplicate samples pooled from 5 independent
experiments. *P , 0.05; **P , 0.01; ***P , 0.001 vs. WT T cells stimulated by TCR-XL, PHA-P, Con A, or PMA + ionomycin. (F) Proliferation of
naı¨ve WT splenic CD4+ T cells upon activation by plate-bound anti-CD3e mAb (open bars) or plate-bound anti-CD3e mAb plus soluble anti-CD28
mAb (solid bars), with or without anti-CD47 mAb miap301 at 1 or 20 mg/ml. Means 6 SEM of triplicate samples, n = 3 independent experiments.
(G) Naı¨ve WT splenic CD4+ T cells were activated with PMA + ionomycin, Con A, or PHA-P in the absence (open bars) or presence (solid bars) of
20 mg/ml anti-CD47 mAb miap301. Data are means 6 SEM of triplicate samples, n = 3 independent experiments.
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cellular mechanisms that lead to protection of Cd472/2 mice in
the MOG35–55-induced EAE model.
Although our data identify defects in T cell integrins as the
dominant mechanism for failure of clonal cell expansion with
resulting increased apoptosis, we suggest that defects in integrin
functions in DCs and monocytes also contribute to protection in
EAE. Prior studies found impaired DC migration to LNs upon
antigen immunization in vivo in Cd472/2 animals [39, 40]. Other
investigators found that anti-CD47 mAb miap301 blocked
monocyte transmigration across brain endothelial monolayers in
a murine in vitro model [41]. Although the authors of these
publications did not identify a role for CD47 regulation of
leukocyte integrins, we propose such a defect would have
contributed to impaired myeloid cell migration. The latter report
also found that blocking mAb to monocyte SIRPa or to
endothelial CD47 also attenuated transmigration, further impli-
cating the CD47-SIRPa pathway in monocyte recruitment.
A surprising result was that although the anti-CD47 mAb
miap301 was found to block CD47 binding to murine SIRPa [24]
and reduced Th1 T cell arrest on ICAM-1 and VCAM-1 (Fig. 1D),
the mAb did not block naı¨ve CD4+ T cell proliferation in vitro
induced by Con A or PHA-P lectins or TCR-XL, as shown in Fig.
7G. The blocking effect of this mAb on adhesion of murine
T cells to ICAM-1 and VCAM-1 was proportional to the level of
inhibition of human T cell arrest on ICAM-1 and VCAM-1 by anti-
human CD47 mAb (Fig. 1D) that also blocked CD47 binding to
SIRPa [42, 43]. We did not, however, predict the lack of
inhibition on T cell proliferation by miap301 mAb, and differ-
ences in results between T cells deficient in CD47 and the anti-
CD47 antibody treatment remain unexplained. A likely expla-
nation is that mAb miap301 does not fully block CD47 in cis and
in trans association with other proteins required in proliferation
of T cells and potentially other immune cells. Alternatively,
perhaps CD47 performs actions that promote proliferation in the
absence of binding ligand. We previously reported that miap301
mAb stained WT T cells, neutrophils, monocytes, and endothelial
cells but not these same cell types from Cd472/2 animals,
indicating specificity for murine CD47 [26]. We speculate that
miap301 mAb interferes with in cis CD47-integrin association as a
result of steric hindrance, but this clearly requires future study.
Our results with the miap301 mAb provide some insight into the
previous report by Han and colleagues [14] that coadministra-
tion of MOG35–55 with anti-CD47 mAb reduced paralysis, whereas
mAb, given at peak of paralysis, worsened disease (a Janus-like,
opposing effect). We speculate that worsening paralysis by mAb
miap301 infusions is a result of impaired recruitment and/or
proliferation of T regulatory cells or other cell types that
normally dampen the immune response to MOG35–55 [44–48].
On the other hand, it is difficult to predict the outcome when
using rat anti-mouse blocking mAb to CD47 interactions in vivo
as a result of short half-life of a rat mAb in mice and of CD47
multiple in cis and in trans partners in immune and nonimmune
(i.e., endothelium and epithelium) cell types. Given the
emerging role of antibodies that target CD47 or SIRPa as an
immunotherapy in cancer models [49, 50], a better under-
standing of the effect of current or newly generated mAb on
CD47 binding to SIRPs or impairing leukocyte or endothelial cell
integrin functions is important.
Han and colleagues [14] recently reported that Cd472/2 mice
were protected in the MOG35–55-induced EAE model as a result
of complete failure in T cell activation. Our much more in-depth
in vivo and in vitro studies do not support this conclusion. It is
likely the differences are related to their not appreciating that
CD47 is necessary for LFA-1 integrin function in adhesion and
antigen- and lectin-dependent proliferation. These authors also
did not appreciate prior reports demonstrating that Cd472/2 cells
injected into WT animals do not survive [5, 15]. Thus, their
conclusion that Cd472/2 T cells isolated from MOG35–55-immunized
Cd472/2mice and then transferred into WT did not cause disease is
not interpretable.
Prior studies supported an important role for CD47 and its
ligands SIRPa and TSP-1 in immune-mediated disease and as a
potential therapeutic target in such diseases. Knock-in Tg mice
expressing a nonsignaling, truncated SIRPa molecule are also
protected in MOG35–55-induced EAE as a result of failure of DCs
to prime T cells and to proliferate [51] and in a collagen-induced
arthritis model [52, 53]. Tsp12/2 mice also show milder disease
in EAE [54]. We suggest the Janus-like, opposing effect of CD47
does not negate its value as a therapeutic target based on the
literature. Notably, initial studies that targeted other therapeu-
tically important immune molecules, including CTLA-4, VLA-4,
and CD28, have also reported Janus-like opposing effects before
their functions in immune cells were fully understood [55–58].
We conclude that lack of sustained LFA-1 integrin-dependent
proliferation in Cd472/2 CD4+ T cells upon MOG35–55
immunization is the major mechanism for protection in the
MOG35–55-induced EAE model, although we do not discount
the potential contribution of impaired T cell homing and/or
recruitment of T effector cells (regulatory T cells, Th1, or
Th17) or myeloid to the CNS.
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